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Introduction. Obesity and obstructive sleep apnea syndrome (OSA) are common coexisting conditions associated with a chronic
low-grade inflammatory state underlying some of the cognitive, metabolic, and cardiovascular morbidities. Aim. To examine the
levels of inflammatory markers in obese community-dwelling children with OSA, as compared to no-OSA, and their association
with clinical and polysomnographic (PSG) variables.Methods. In this cross-sectional, prospective multicenter study, healthy obese
Spanish children (ages 4–15 years) were randomly selected and underwent nocturnal PSG followed by a morning fasting blood
draw. Plasma samples were assayed for multiple inflammatory markers. Results. 204 children were enrolled in the study; 75 had
OSA, defined by an obstructive respiratory disturbance index (RDI) of 3 events/hour total sleep time (TST). BMI, gender, and age
were similar in OSA and no-OSA children. Monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1
(PAI-1) levels were significantly higher in OSA children, with interleukin-6 concentrations being higher in moderate-severe OSA
(i.e., AHI > 5/hrTST; 𝑃 < 0.01), while MCP-1 levels were associated with more prolonged nocturnal hypercapnia (𝑃 < 0.001).
Conclusion. IL-6, MCP-1, and PAI-1 are altered in the context of OSA among community-based obese children further reinforcing
the proinflammatory effects of sleep disorders such as OSA. This trial is registered with ClinicalTrials.gov NCT01322763.
1. Introduction
Sleep-disordered-breathing (SDB) is a group of common dis-
orders characterized by habitual snoring along with varying
degrees of gas exchange alterations and sleep fragmentation
[1]. Obstructive sleep apnea (OSA) is the most prevalent
of those disorders affecting 1–4% of children with a peak
incidence around 2–8 years [2]. In recent years, it has become
apparent that the frequency of OSA is markedly increased by
the concurrent presence of obesity [3] and the coexistence
of these 2 conditions has been linked to a higher risk
for development of end-organ morbidities, including neu-
rocognitive and behavioral impairments and cardiovascular
and metabolic dysfunction [4–8]. In addition to increased
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oxidative stress, activation and propagation of inflammatory
pathways in the context of immune dysregulation have been
implicated in the deleterious consequences of OSA [9, 10],
with the cumulative evidence strongly supporting the concept
that pediatric OSA is a chronic, low grade inflammatory con-
dition [11–16]. In this context, it is now recognized that OSA
causes, albeit not always, systemic elevation in the levels of
inflammatorymediators, such asCRP,TNF𝛼, IL-6, and INF-𝛾
[17–23], and the concomitant reduction of anti-inflammatory
substances, such as IL-10, thereby tilting the balance toward
a heightened proinflammatory state [24].
Similarly, obesity has long been recognized as an indolent
andpersistent inflammatory condition inwhich the sustained
activity of such processes promotes the occurrence of insulin
resistance and vascular dysfunction [25–29]. OSA and obe-
sity frequently coexist in children and have been assumed to
interact and promote each other [30–32].
However, the potential contributions ofOSA to the proin-
flammatory profile of obese children have not been critically
delineated, particularly considering the incongruent inflam-
matory phenotypes that have been previously reported in
obese children [33]. Thus, we hypothesized that community-
recruited obese children with OSA would display significant
differences in their plasma levels of specific biomarkers, in-
cluding inflammatory markers. The aim of the present study
was to assess and better delineate the potential effects of per-
turbed sleep, such as occurs in OSA, on a panel of inflam-
matory cytokines and adipokines in a large cohort of obese
children.
2. Subjects and Methods
204 obese children (ages 4–15 years) were recruited from the
community in a multicenter prospective study in Spain—
the NANOS study. A detailed account of the study design is
described elsewhere [34]. Briefly, obese children were pro-
spectively enrolled through primary care centers across Spain
during 2007–2010 and were randomly selected to participate
in the study. The study was approved by a human subject
committee in each of the participating centers and is in ac-
cordance with the STROBE statement. The study was reg-
istered at ClinicalTrials.gov under NCT01322763. Informed
consent was obtained from each subject or legal guardian,
and assent was obtained from children above 12 years old.
Data was coded so each investigator in the research network
was blinded to subjects’ personal information and thus ensur-
ing confidentiality. Samples and data from subjects included
in this study were provided by the Basque Biobank for
researchOEHUN(http://www.biobancovasco.org/) andwere
processed following standard operating procedures with ap-
propriate approvals from the Ethical and Scientific Commit-
tees.
The general medical and sleep histories were obtained
from all participating children and the parents filled a val-
idated Spanish version of the Pediatric Sleep Questionnaire
(PSQ) [35]. Every child then underwent a thorough medical
examination followed by an overnight sleep study (PSG).
The morning after the PSG, blood was drawn in fasting
conditions.
2.1. Overnight Polysomnography. PSG testswere conducted in
a sleep laboratory under standardized conditions.The studies
were scored, after removal of movement and technical arti-
facts, according to the standard criteria defined by the Amer-
ican Academy of Sleep Medicine (AASM) [36]. Briefly, ob-
structive sleep apnea was defined as cessation of airflow with
continued chest wall and abdominalmovements for the dura-
tion of at least of two breaths. Hypopnea was defined as a
decrease in nasal flow greater than 50%, corresponding to at
least 4% decrease in the oxygen saturation (SpO
2
) as mea-
sured by pulse oximetry and/or terminated by a 3-second
EEG arousal. The obstructive apnea-hypopnea index (AHI)
was defined as the number of apneas and hypopneas per hour
of total sleep time (TST). The obstructive respiratory distur-
bance index (RDI) was calculated from the number of respir-
atory-effort-related arousals and the number of apneas and
hypopneas per hour of TST. Children with OSA were defined
as those having RDI ≥ 3/hr of TST in accordance with the
clinical practice guidelines in Spain [37]. In addition, nadir
andmean SpO
2
, as well total sleep time during which SpO
2
is
below 90% or end-tidal CO
2
> 50mmHg occurred, were re-
corded. Oxygen desaturation index (ODI) was defined as the
number of desaturation events≥ 4%per hour of TST.Of note,
in our subanalyses we defined moderate-to-severe OSA, as
the presence of obstructive AHI > 5/hrTST.
2.2. Inflammatory Mediator Assays. Plasma was separated
from the whole blood morning samples drawn from each
child and stored in −80∘C until assay. Commercially available
ELISA kits specific for each cytokine were used to measure
levels of IL-6, IL-18, MCP-1, adiponectin, MMP-9, apelin C,
leptin (all individual kits from RayBiotech, Inc., Norcross,
GA, USA), adropin (Peninsula laboratories LLC, San Carlos,
CA, USA), osteocrin (MyBioSource, San Diego, CA, USA),
and PAI-1 (Assaypro LLC, St. Charles, MO, USA). Assays
were performed according to manufacturers’ recommenda-
tions.
2.3. Statistical Analysis. Descriptive data for continuous vari-
ables are presented as means ± standard deviation (SD) and
for categorical variables as percentages or ratios. Analyses for
comparisons between clinical and laboratory values among
OSA and no-OSA groups were performed using Student’s t-
tests for continuous and 𝜒2 tests for categorical variables fol-
lowed by Fisher exact tests. Group comparisons were con-
ducted using one-way ANOVA followed by Bonferroni cor-
rection for multiple comparisons. Pearson’s correlation was
used to compare between the marker levels and clinical
parameters. Multivariate linear regression analysis was ap-
plied to assess relationships of significantly different markers
between the two groups of children. Statistical significance
was assumed at two-tailed 𝑃 < 0.05. Statistical analyses were
performed using SPSS software (version 21.0; SPSS Inc.,
Chicago, IL).
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Table 1: Antropometric measures in OSA and no-OSA obese children.
Total (𝑛 = 204) No-OSA (𝑛 = 129) OSA (𝑛 = 75) 𝑃 value
Age (years) 10.8 ± 2.6 11 ± 2.4 10.4 ± 2.8 0.1
Gender (male/female) 111/93 72/57 39/36 0.6
Height (m) 1.5 ± 0.16 1.5 ± 0.16 1.46 ± 0.17 0.1
Weight (Kg) 64.3 ± 21.1 65.2 ± 20.6 62.7 ± 22.1 0.4
BMI 27.9 ± 4.3 27.9 ± 4.1 28 ± 4.6 0.8
BMI% 96.8 ± 0.6 96.7 ± 0.6 96.8 ± 0.4 0.4
Neck circumference (cm) 34.1 ± 3.8 33.9 ± 3.8 34.3 ± 3.7 0.5
Waist circumference/hip circumference 0.9 ± 0.07 0.9 ± 0.07 0.9 ± 0.07 0.6
∗Data presented as mean ± SD.
Table 2: Polysomnographic characteristics in OSA and no-OSA obese children.
Total (𝑛 = 204) No-OSA (𝑛 = 129) OSA (𝑛 = 75) 𝑃 value
AHI (/hrTST) 3.6 ± 9.5 0.6 ± 0.6 9 ± 14.2 <0.001†
Time in Bed (min) 479.2 ± 45.8 482.8 ± 47 473.1 ± 43.4 0.1
Total sleep time (min) 379.6 ± 70.2 384.1 ± 70.7 372 ± 69.4 0.2
Sleep Efficiency% 78.9 + 12.8 78.9 ± 12.3 78.9 ± 13.9 0.9
Number of arousals 67.3 ± 62.5 48.2 ± 32.9 99.4 ± 84.1 <0.001†
Arousal index (/hrTST) 11.2 ± 11.2 7.9 ± 6.1 17 ± 15.1 <0.001†
Respiratory disturbance index (/hrTST) 6 ± 10.6 1.4 ± 1 14 ± 14.5 <0.001†
Obstructive RDI (/hrTST) 5.5 ± 10.3 1 ± 0.9 13.3 ± 13.9 <0.001†
Central RDI (/hrTST) 0.3 ± 1 0.2 ± 0.4 0.6 ± 1.7 0.01†
Baseline SpO2 (%) 98.1 ± 1.4 98.3 ± 1.3 98 ± 1.7 0.2
Mean SpO2 (%) 96.4 ± 1.5 96.7 ± 1.2 96.1 ± 1.9 0.008
†
Nadir SpO2 (%) 90.5 ± 5.2 91.4 ± 3.5 89.1 ± 7 0.003
†
Time SpO2 < 90% 1.1 ± 7.2 0.5 ± 3.3 2.3 ± 11.4 0.1
Oxygen desaturation index (/hrTST) 2.3 ± 9 0.7 ± 1.2 5.1 ± 14.2 0.001†
Peak end-tidal CO2 (mmHg) 46.2 ± 6.9 46.1 ± 6.1 46.2 ± 8.3 0.9




3.1. Demographic Data. 204 obese children from the commu-
nity (ages 4–15 years) were recruited from the NANOS study,
111 boys and 93 girls, all fulfilling obesity criteria, that is, BMI
above the 95% for age and gender [38]. The prevalence of
OSA in this group of obese children was 36.7%.The 2 groups
of children, those with (OSA) and without OSA (no-OSA),
had similar demographic and anthropometric characteristics
(Table 1).
3.2. Sleep Studies. PSG findings are summarized in Table 2
for the 2 groups. As would be anticipated from the OSA and
no-OSA category allocation, most of the PSG variables dif-
fered, and most particularly for respiratory parameters and
the number of arousals from sleep (Table 2). In contrast, there
were no significant differences in either the total duration of
sleep and total time in bed (Table 2). These findings support
the idea that disruption of sleep architecture, that is, sleep
fragmentation, rather than sleep deprivation, is the salient
sleep perturbation among children with OSA [4].
3.3. Plasma Inflammatory Mediators in Obese Children: OSA
versus No-OSA. Among the inflammatory markers included
in the present study, 2 markers were significantly higher in
the OSA group, namely, PAI-1 (Table 3; 𝑃 = 0.01) andMCP-1
(Table 3; 𝑃 = 0.03). In a subset of children with more severe
OSA (i.e., AHI > 5/hrTST), significantly higher levels of IL-
6 emerged (𝑃 = 0.009; Table 3). In addition, MCP-1 levels
of ≥30 pg/mL and PAI-1 of ≥3.3 ng/mL conferred a modestly
higher risk of OSA (OR = 2, CI
95% = 1.1–3.6, 𝑃 = 0.02; OR =
1.8, CI
95% = 1–3.2, 𝑃 = 0.04, resp.).
To further examine the global contribution of inflamma-
tory markers to the overall inflammatory state of each child,
we constructed a cumulative “inflammatory score” (IS),
whereby each marker was standardized using z-score trans-
formation.The IS was then calculated by summarizing all the
individual z scores. Please note that the z scores for adi-
ponectin and adropin were calculated and multiplied by −1,
since their plasma levels have been reported to decrease in
states of increased inflammation and obesity. The IS was
significantly higher in the OSA as compared to no-OSA
groups (Table 3; 𝑃 = 0.04).
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Table 3: Inflammatory markers in OSA and non-OSA obese children.
Total (𝑛 = 204) No-OSA (𝑛 = 129) OSA (𝑛 = 75) 𝑃 value
IL-6 (pg/mL) 7.5 ± 3.8 7.3 ± 3.2 8 ± 4.8 0.2
[7–8.1] [6.7–7.8] [6.8–9.1]
IL-18 (pg/mL) 170.2 ± 96.8 163.2 ± 80.8 182.4 ± 119.2 0.17
[156.9–183.6] [149.1–177.2] [155.1–209.9]
PAI-1 (ng/mL) 3.3 ± 1.2 3.2 ± 1.2 3.6 ± 1.3 0.01†
[3.1–3.5] [2.9–3.4] [3.3–3.9]
MCP-1 (pg/mL) 35.1 ± 16.9 33.2 ± 15.2 38.4 ± 19.1 0.03†
[32.8–37.5] [30.6–35.9] [34–42.8]
Apelin C (ng/mL) 127.9 ± 118.9 125.9 ± 80.8 131.3 ± 165.8 0.7
[111.5–144.3] [111.9–140] [93.1–169.4]
Adropin (ng/mL) 0.8 ± 0.3 0.8 ± 0.3 0.87 ± 0.32 0.1
[0.79–0.87] [0.75–0.85] [0.79–0.94]
Adiponectin (𝜇g/mL) 28.1 ± 13.3 26.8 ± 12.1 30.3 ± 14.9 0.07
[26.2–29.9] [24.6–28.9] [26.8–33.7]
MMP-9 (𝜇g/mL) 0.9 ± 0.6 0.9 ± 0.5 1 ± 0.8 0.1
[0.85–1] [0.8–0.97] [0.85–1.2]
Osteocrin (ng/mL) 8.5 ± 12.6 7.8 ± 7.2 9.7 ± 18.5 0.3
[6.7–10.2] [6.5–9.1] [5.5–14]
Leptin (ng/mL) 19.1 ± 8.1 18.5 ± 8.2 20 ± 8 0.2
[17.9–20.2] [17.1–19.9] [18.1–21.8]
IS 0 ± 4.3 −0.5 ± 3.4 0.8 ± 5.4 0.04†
[−0.49–4.9] [−1.1–0.13] [−0.43–2.1]
∗Data presented as mean ± SD [CI95%].
†Statistically significant difference; IS: inflammatory cumulative score.
No differences in inflammatory marker levels emerged
between boys and girls in the full cohort, except for higher
plasma levels of leptin among girls (17.1 versus 21.3 ng/mL,
𝑃 < 0.001). Of note, girls had slightly lower baseline and
mean SpO
2
levels during the PSG (mean difference ∼0.5%,
𝑃 = 0.01) and a trend toward lower BMI% (96.8 versus 96.7%,
𝑃 = 0.05).
3.4. Correlation Analyses. First, we examined whether the
various biomarkers were associated with both PSG-derived
measures and anthropometric measurements in the full
cohort (𝑛 = 204; Table 3). Higher MCP-1 levels correlated
with ODI (𝑟 = −0.171; 𝑃 = 0.02), with TCO
2
> 50 (𝑟 =
0.352; 𝑃 < 0.001) and with peak CO
2
levels (𝑟 = 0.168; 𝑃 =
0.02). These correlations remained statistically significant
after adjusting for age, gender, and BMI. Leptin was posi-
tively associated with higher BMI, older age, female gender,
and shorter sleep duration, and such associations remained
significant even after adjusting for other confounders (𝑃 ≤
0.006). Higher leptin levels were also associated with lower
sleep efficiency (after adjusting for age), but this effect disap-
peared when adjusted for BMI. Adiponectin was negatively
correlated with age and BMI (𝑟 = −0.3;𝑃 < 0.001), while age-
adjusted adiponectin levels were borderline associated with
BMI (𝑃 = 0.054).
Additionally, IS had a strong positive correlation with
BMI (𝑟 = 0.241, 𝑃 < 0.001), neck circumference (𝑟 = 0.226,
𝑃 < 0.001), age (𝑟 = 0.154, 𝑃 = 0.01), and TCO
2
> 50 (𝑟 =
0.294, 𝑃 < 0.001) and was inversely associated with TST
(𝑟 = −0.172, 𝑃 = 0.007) and sleep efficiency (𝑟 = −0.142, 𝑃 =
0.026). In a linear regression model that included all of the
above variables that had significant correlations with IS, BMI
and TCO
2
> 50 independently predicted higher IS (𝛽 =
0.296, 𝑃 = 0.001; 𝛽 = 0.360, 𝑃 < 0.001).
Next, we examined whether any of the specific markers
was potentially useful in predicting clinically relevant com-
ponents of sleep-disordered breathing among the 75 children
with OSA, that is, sleep fragmentation, intermittent hypox-
emia, and hypercapnia. Pearson correlation coefficients
(PCC) are presented and only the results that remained sta-
tistically significant after age adjustment are presented below,
given the considerable changes in marker levels as a function
of age (Table 4). Significant associations were observed for
MCP-1 levels and ODI (𝑟 = −0.276; 𝑃 = 0.01), Nadir SpO
2
(𝑟 = 0.232; 𝑃 = 0.02), and TCO
2
> 50 (𝑟 = 0.412; 𝑃 < 0.001).
MCP-1 association with ODI remained significant after ad-
justing for age, sex, and BMI. Leptin was associated with low-
er TST (𝑟 = −0.413, 𝑃 < 0.001). Adropin was associated with
lower total time in bed (𝑟 = −0.363;𝑃 = 0.001), baseline SpO
2
(𝑟 = −0.471; 𝑃 < 0.001), peak CO
2
(𝑟 = −0.389; 𝑃 = 0.001),
and TCO
2
> 50 (𝑟 = −0.335; 𝑃 = 0.007). MMP-9 was asso-
ciated with lower total time in bed (𝑟 = −0.310; 𝑃 = 0.007)
and with higher TCO
2
> 50 (0.273; 𝑃 = 0.03). Finally, apelin
Mediators of Inflammation 5
Table 4: Univariate associations among inflammatory markers and
PSG measures in children with OSA.
Marker Clinical variable PCC 𝑃 value
MCP-1
Oxygen desaturation index −0.276 0.017
Nadir SpO2 0.232 0.02
TCO2 > 50 0.412 0.001
Leptin Total sleep time −0.413 <0.001
Adropin
Total time in bed −0.363 0.001
Baseline SpO2 −0.471 <0.001
TCO2 > 50 −0.335 0.007
Peak CO2 −0.389 0.001
IL-18 Baseline SpO2 −0.290 0.01
MMP-9 TCO2 > 50 0.273 0.03
Total time in bed −0.310 0.007
Apelin C TCO2 > 50 0.511 <0.001
C exhibited a strong positive correlationwith TCO
2
> 50 (𝑟 =
0.511; 𝑃 < 0.001).
In amultivariate analysis that included all themarker lev-
els in the OSA group aiming at correcting for inter-
marker correlations, age-adjusted MCP-1 levels remained the
only inflammatory mediator that independently predicted
TCO
2
> 50 (𝛽 = 0.322, 𝑃 = 0.03). Furthermore, age-adjusted
leptin levels in the OSA group independently predicted lower
TST (𝛽 = −0.252,𝑃 = 0.04). Inflammatory score (IS)was cor-
related in the OSA group with higher TCO
2
> 50 (𝑟 = 0.359,
𝑃 = 0.002) and had borderline association with neck circum-
ference (𝑟 = 0.213, 𝑃 = 0.049). Only higher TCO
2
> 50 inde-
pendently predicted higher IS (𝛽 = 0.356, 𝑃 = 0.003) in the
OSA group in a model that included age, BMI, and neck cir-
cumference.
4. Discussion
Current findings provide incremental evidence that the pres-
ence of OSA operates as an independent contributor to the
increased systemic inflammation that occurs in obese chil-
dren. Our data indicate that the levels of two blood markers,
namely, PAI-1 and MCP-1, were increased among obese
children with OSA, such that plasma concentrations of
MCP-1 > 30 pg /mL and PAI-1 > 3.3 ng/mL provide reliable
prediction on the presence of OSA. In addition, in a subset of
obese children with moderate-to-severe OSA, IL-6 levels
were also significantly higher. Furthermore, the overall in-
flammatory status, as inferred from the inflammatory score
(IS), an arbitrary additive summation of the relative levels of
all the current markers assayed in this study, was significantly
increased in the OSA group, indicating heightened overall
inflammatory load in OSA. Interestingly, IS also exhibited
significant associations with BMI and total sleep time and
efficiency as well as with the duration of hypercapnia.
Before discussing the potential implications of our find-
ings, we will initially focus on those 3 inflammatory media-
tors that were markedly elevated in the OSA group, MCP-1,
PAI-1, and IL-6. Monocyte chemoattractant protein 1 (MCP-
1) is a central member of the C-C chemokine superfamily
responsible for attracting mononuclear cells to inflammatory
sites [39].MCP-1 increaseswith obesity, plays a role in recruit-
ing macrophages into adipose tissue in adult obese patients
[40–42], and is associated with insulin resistance and with
type 2 diabetes [43]. This cytokine, which is also highly ex-
pressed in the inflamed vasculature, is a potent attractor of
lipid-activated monocytes involved in the inflammatory sig-
naling cascade related to vascular dysfunction, atheroscle-
rosis, and cardiac events [44, 45]. In children, there is also
evidence that MCP-1 increases with obesity [46, 47]. In the
context ofOSA,MCP-1 elevations have been reported in adult
patients, and treatment with CPAP reducedMCP-1 levels [48,
49]. The negative association reported herein between ODI
and MCP-1 levels was unexpected considering that MCP-1
gene expression increases in response to hypoxia and appears
to correlate with the degree of hypoxemia in adult patients
with OSA [50]. PAI-1 is an inhibitor of tissue plasminogen
activator and primarily functions as a suppressor of plasma
fibrinolysis. PAI-1 increases in plasma are believed to play a
role in the pathophysiology of endothelial dysfunction and
atherothrombosis [51]. PAI-1 has been recently shown to
have a strong correlation with known cardiometabolic risk
factors in adults and is proposed as a biomarker formetabolic
syndrome [52]. Similarly, higher PAI-1 levels have been
associated with higher risk for microvascular complications
in children, as well as with poorer diabetes control and hyper-
lipidemia in patients with type 1 diabetes [53]. In the context
of OSA, higher levels of PAI-1 have been previously described
in adults [54, 55]. Here, we show for the first time that obese
children with OSA have higher plasma levels of PAI-1,
supporting the notion that such alterations may reflect an
underlying risk for vascular dysfunction, even if measures
of endothelial functionwere not specifically acquired. Indeed,
early development of endothelial dysfunction in pediatric
OSA has been the subject to recent and intense research ef-
forts which have led to the demonstration that the microvas-
cular bed is a target of OSA [7, 8, 56–58]. Interleukin-6 is a
ubiquitously expressed proinflammatory cytokine and well-
established risk factor for adverse cardiovascular outcomes
[59]. IL-6 signaling pathways are involved in the liver syn-
thesis of C-reactive protein (CRP), and CRP is elevated in
children with sleep-disordered breathing, whereby both IL-6
and CRP levels correlate with degree of hypoxemia and sleep
disruption, independently of the degree of obesity [60]. Ele-
vated IL-6 levels have been now repeatedly described in both
adults and children with OSA [61, 62], and genetic variations
in the IL-6 gene are associated with pediatric OSA and may
account for the increased CRP levels seen in those children
[23]. Thus, the increased IL-6 levels in the moderate-severe
group of OSA children may provide a useful indicator for
the presence of a more severe clinical phenotype. However,
we cannot exclude the possibility that the different genomic
background in this population may account for a decreased
likelihood of finding elevated IL-6 plasma concentrations as
recently reported in a comparison of US and Greek children
[23].
Our study is the first to examine a large pediatric cohort
of obese children from the community (i.e., not clinically
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referred children) and evaluated these children in an unbi-
ased fashion for the presence of sleep-disordered breathing.
These were therefore a priori healthy children without any
preexisting conditions except for the presence of obesity. All
previous studies in which the proinflammatory effects and
metabolic consequences of obesity were explored consisted of
symptomatic, clinically-referred obese children being evalu-
ated for management of their obesity and with a high prev-
alence of OSA, precluding systematic determination of the
relative contribution of OSA to the inflammatory profile of
obesity [3, 18, 19, 63, 64]. As reported above, the increase in
individual inflammatorymarkers and in the overall IS among
theOSA groupwas independent of the degree of obesity. Fur-
thermore, all 3 markers altered by OSA are ascribed patho-
physiological roles in cardiovascular dysfunction, thereby
suggesting thatOSA in obese childrenmight predispose them
to a more severe cardiovascular phenotype and to earlier de-
velopment of cardiovascular morbidities. Based on our pre-
vious study showing that obese children with OSA have a
significantly higher proportion of abnormal endothelial func-
tion [7], more aggressive diagnostic and intervention mea-
sures appear to be warranted by the concurrent presence
of obesity and symptoms of OSA. Conversely, children with
milder forms of sleep-disordered breathing, that is, RDI < 3/
hrTST, had lower systemic inflammatorymarkers, potentially
justifying the expectant approach strategy as recently recom-
mended [65].
An interesting association emerged between increased
BMI and leptin levels and decreased total sleep time during
the overnight PSG. Such association concurs with epidemi-
ological studies showing that sleep loss is associated with
increased obesity, increased appetite, and elevated leptin lev-
els in adults [66], and with similar recent findings in children
[67]. Of note, reduced duration is not a primary feature of
OSA, as confirmed by the similar total sleep time in OSA and
no-OSA children in the present study.
The strong association between prolonged hypercapnia
and increased inflammation deserves comment. Obesity-
hypoventilation syndrome (OHS) is a relatively infrequent
condition in children that is characterized by airway obstruc-
tion and CO
2
retention [68]. OHS is relatively underdiag-
nosed, and in adults it has been associatedwith impaired daily
functioning and increased risk for diabetes and cardiovascu-
lar morbidity (including systemic and pulmonary hyperten-
sion, ischemic heart disease, and right-heart failure), as well
as with higher risk of hospitalization and death [69–72]. The
occurrence of alveolar hypoventilation during sleep is much
more common in obese children with OSA when compared
with children with OSA who are not obese [73, 74], and the
present study illustrates for the first time the possibility that
children with increased CO
2
retention may represent a high
risk group.
In summary, systemic inflammation is more pronounced
in obese children with OSA, further buttressing the contri-
butions of perturbed sleep and gas exchange abnormalities to
the inflammatory cascade. Further studies are needed to in-
vestigate the role of PAI-1 as a marker of endothelial dysfunc-
tion and the role of hypercapnia on increased inflammation
and end-organ injury in obese and nonobese children with
OSA.
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